Sarawak has established itself as Malaysia’s leading state for first-in-human clinical trials, with Sarawak General Hospital (SGH) at the forefront of testing innovative cancer treatments. Deputy Premier Dr. Sim Kui Hian highlighted that the state has now conducted eight such groundbreaking trials, contributing significantly to the development of new oncology drugs worldwide. Of the 25 new cancer drugs developed and marketed globally, eight have been tested in Sarawak.
“Before last year, Malaysia had never conducted a first-in-human trial. There was a lack of trust and concerns about our capabilities,” Dr. Sim said at the 5th ASEAN International Oncology Integrative Medicine Session. “But since last year, five first-in-human trials have been carried out in Malaysia, with SGH responsible for four of them. There are four more trials underway this year.”
First-in-human trials mark the critical phase of testing new drugs on humans for the first time, playing an essential role in the discovery of life-saving cancer therapies. Dr. Sim emphasized that these milestones have put Sarawak on the global research map, proving that local expertise meets international standards.
“This progress signals that we are no longer viewed as a third-world country. Without first-in-human trials, new cancer drugs cannot be developed,” he explained.
To date, Sarawak has hosted 155 clinical trials, ranking it among the top contributors out of 267 trial sites across Malaysia. Dr. Sim noted that such trials are governed by rigorous international standards, monitored not only by Malaysian authorities but also by global pharmaceutical companies.
“Worldwide, only about 30 sites meet these high standards. To qualify, you must be a top-tier centre,” he said.
Despite these achievements, Dr. Sim expressed concern over the current state of SGH’s cancer centre facilities. “When patients come to the cancer department here, they often leave sicker because the facilities are outdated and below standard,” he lamented.
Funding for upgrades has been a challenge, with the federal government citing financial constraints. In response, the Sarawak government has proposed a partnership approach, pledging an initial RM1 billion to improve the cancer centre. Dr. Sim urged swift action, saying, “If that’s not enough, we welcome further support from the federal government when funds become available. Waiting is not an option — lives are at stake, and saving them must come first.”
